Menu
FDA · Medical device recall

Centricity PACS Software Version 7.0 SP0.0.4.7

Aug. 3, 2022 Class II

Date
Aug. 3, 2022
Risk class
Class II (FDA's definition, 21 CFR 7.3(m): a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote)
Status
Terminated
Filed by
GE Healthcare, LLC
Product
Centricity PACS Software Version 7.0 SP0.0.4.7
Reason
The Event Notification Manager (ENM) functionality for certain products does not process notifications for study modifications performed on post verified exams.
Distribution pattern
Worldwide distribution - US Nationwide distribution in the states of CO, NV, OH, PA, WA and the countries of Brazil, Canada, China, France, Germany, Israel, Italy, Japan, Oman, Spain, Switzerland, and United Kingdom.
Quantity
47 installations
Codes and lots
Model: 5831882-012, Software Version 7.0 SP0.0.4.7 GTIN: 00840682145572
Recall started
June 14, 2022
Device type
System, Image Processing, Radiological
Root cause (FDA)
Software design
What the company told customers
An Urgent Medical Device Correction letter was sent to customers beginning June 14, 2022. The letter informs the customer of the issue and provides safety instructions for continued use of the device. GE Healthcare will correct all affected devices via a software update. In the U.S., this letter will be sent by a traceable means. This letter will be sent to the following titles within the affected accounts: Director/Manager of Radiology, Director/Manager of Cardiology, Risk Manager/Hospital Administrator, Head of Radiology Department, Head of Cardiology Department, PACS Administrator, Director of IT Department, Head of Biomedical Engineering, Head of Imaging Informatics.
Recall number
Z-1466-2022

What should I do? How serious is a recall? Classes and warnings explained

Source: FDA · Medical device enforcement report, recall number Z-1466-2022. The agency record governs; check it and the company before acting.

Report a mistake on this page